https://scholars.lib.ntu.edu.tw/handle/123456789/558532
標題: | Does pemetrexed work in targetable, nonsquamous non-small-cell lung cancer? A narrative review | 作者: | JIN-YUAN SHIH Inoue A. Cheng R. Varea R. Kim S.-W. |
關鍵字: | Chemotherapy; Gain of function mutation; Non-small-cell lung cancer; Pemetrexed; Progression-free survival | 公開日期: | 2020 | 出版社: | MDPI AG | 卷: | 12 | 期: | 9 | 起(迄)頁: | 1-18 | 來源出版物: | Cancers | 摘要: | Pemetrexed is currently mainly considered for the treatment of advanced nonsquamous non-small-cell lung cancer (NSCLC) negative for gene mutations/rearrangements (wild-type disease (WTD)). This narrative review aimed to highlight the role of pemetrexed in the treatment of onco-driven nonsquamous advanced NSCLC by reviewing published clinical studies. For epidermal growth factor receptor (EGFR) mutations, patient survival following first-line pemetrexed–platinum was longer than for WTD. Later-line pemetrexed-based treatment after tyrosine kinase inhibitor (TKI) failure provided greater benefits than non-pemetrexed regimens. First-and later-line pemetrexed-based therapy also provided survival benefits in patients with anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1 (ROS1) rearrangements. In patients with rearranged during transfection (RET) proto-oncogene rearrangements, survival with pemetrexed was similar to that in ALK-and ROS1-positive patients and longer than that in patients with Kirsten rat sarcoma (KRAS) virus proto-oncogene mutations or WTD, although the available studies were limited. For Erb-b2 receptor tyrosine kinase 2 (ERRB2) mutations, first-line pemetrexed showed outcomes similar to those for EGFR and KRAS alterations. Data on pemetrexed in patients with KRAS mutations or MNNG HOS-transforming (MET) expression were limited. Pemetrexed could be an option for first-and second-line treatment for TKI failure in nonsquamous advanced NSCLC with select targetable driver mutations. ? 2020 by the authors. Licensee MDPI, Basel, Switzerland. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091141306&doi=10.3390%2fcancers12092658&partnerID=40&md5=823f78632fad316eca7065154476a0f5 https://scholars.lib.ntu.edu.tw/handle/123456789/558532 |
ISSN: | 2072-6694 | DOI: | 10.3390/cancers12092658 | SDG/關鍵字: | afatinib; alectinib; anaplastic lymphoma kinase; atezolizumab; brigatinib; cabozantinib; capmatinib; carboplatin; ceritinib; cisplatin; crizotinib; dabrafenib; dacomitinib; durvalumab; entrectinib; epidermal growth factor receptor; erlotinib; gefitinib; K ras protein; larotrectinib; lorlatinib; nivolumab; osimertinib; pembrolizumab; pemetrexed; selpercatinib; selumetinib; trametinib; trastuzumab; advanced cancer; cancer combination chemotherapy; EGFR gene; ERRB2 gene; gene expression; gene mutation; gene rearrangement; HER2 gene; human; monotherapy; non small cell lung cancer; oncogene K ras; progression free survival; proto oncogene; RET gene; Review; ROS1 gene |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。